(Bloomberg) -- Roche Holding AG’s breast cancer medicine Perjeta succeeded in the drugmaker’s most hotly anticipated patient study, bolstering a franchise that could exceed $9 billion in sales by 2021.
Patients who took Perjeta alongside Roche’s widely used Herceptin and chemotherapy regimen after surgery for early breast cancer lived for longer without dying or seeing their breast tumors return than those on the older treatments alone, Roche said in a statement Thursday. The safety profile was consistent with previous studies.
To contact the reporter on this story: Naomi Kresge in Berlin at email@example.com.
To contact the editors responsible for this story: Chitra Somayaji at firstname.lastname@example.org, Marthe Fourcade, Chad Thomas
©2017 Bloomberg L.P.